Olopatadine
| Code | Size | Price |
|---|
| TAR-T21462-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Olopatadine, an antihistamine, as well as anticholinergic and mast cell stabilizer, is used for the treatment of itching associated with allergic conjunctivitis (eye allergies). There is also a potential for Olopatadine to treat steroid rebound (red skin syndrome).
CAS:
113806-05-6
Formula:
C21H23NO3
Molecular Weight:
337.419
Purity:
0.98
SMILES:
CN(C)CCC=C1c2ccccc2COc2ccc(CC(O)=O)cc12
References
1. Olopatadine for the Treatment of Allergic Conjunctivitis: A Review of the Clinical Efficacy, Safety, and Cost-Effectiveness [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Mar 17. Available from http://www.ncbi.nlm.nih.gov/books/NBK355639/ PubMed PMID: 27077162.
2. Nickels AS, Dimov V, Wolf R. Pharmacokinetic evaluation of olopatadine for the treatment of allergic rhinitis and conjunctivitis. Expert Opin Drug Metab Toxicol. 2011 Dec;7(12):1593-9. doi: 10.1517/17425255.2011.630389. Epub 2011 Oct 28. Review. PubMed PMID: 22032416.
3. Roland PS, Ryan MW, Wall GM. Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older. Expert Opin Pharmacother. 2010 Jun;11(9):1559-67. doi: 10.1517/14656566.2010.485609. Review. PubMed PMID: 20482305.
4. Leonardi A, Quintieri L. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell. Expert Opin Pharmacother. 2010 Apr;11(6):969-81. doi: 10.1517/14656561003694643. Review. PubMed PMID: 20307221.
5. Ge S, Wang X, Hou Y, et al. Repositioning of histamine H1 receptor antagonist: Doxepin inhibits viropexis of SARS-CoV-2 Spike pseudovirus by blocking ACE2[J]. European Journal of Pharmacology. 2021: 173897.